scholarly article | Q13442814 |
P356 | DOI | 10.1111/TID.12232 |
P8608 | Fatcat ID | release_kv5v7rhqj5cb5aq2nen3mvoc64 |
P698 | PubMed publication ID | 24834833 |
P50 | author | Joan Gavaldà | Q40625420 |
Oscar Len | Q42234079 | ||
Núria Sabé | Q42253913 | ||
Elisa Cordero | Q43130677 | ||
Pilar Martín-Dávila | Q52287220 | ||
Carlos Cervera | Q57951489 | ||
P2093 | author name string | A Ramos | |
J Torre-Cisneros | |||
M Montejo | |||
A Pahissa | |||
J R Azanza | |||
M C Fariñas | |||
DAPTOSOT (Daptomycin in Solid Organ Transplantation) Study Group | |||
P2860 | cites work | The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections | Q34330270 |
Vancomycin: a 50-year reassessment | Q34472258 | ||
Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus | Q34558111 | ||
Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia | Q34783668 | ||
Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects | Q34882125 | ||
Rapid bactericidal activity of daptomycin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus peritonitis in mice as measured with bioluminescent bacteria | Q35759049 | ||
The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus | Q36779557 | ||
Multicenter study of high-dose daptomycin for treatment of enterococcal infections | Q37124177 | ||
Daptomycin therapy for vancomycin-resistant enterococcal bacteremia: a retrospective case series of 30 patients | Q37532488 | ||
Successful salvage therapy with Daptomycin for osteomyelitis caused by methicillin-resistant Staphylococcus aureus in a renal transplant recipient with Fabry-Anderson disease | Q41858729 | ||
Vancomycin-resistant Enterococcus infections in solid organ transplantation | Q42272348 | ||
Efficacy and safety of daptomycin in the treatment of Gram-positive catheter-related bloodstream infections in cancer patients | Q43069045 | ||
High-dose daptomycin for cardiac implantable electronic device-related infective endocarditis | Q43443557 | ||
Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy | Q44959085 | ||
Successful salvage therapy with daptomycin after linezolid and vancomycin failure in a liver transplant recipient with methicillin-resistant Staphylococcus aureus endocarditis. | Q45982608 | ||
An HPLC assay for daptomycin in serum | Q46340635 | ||
Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia | Q46826194 | ||
Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection. | Q54174345 | ||
Vancomycin-resistant Enterococcus bacteremia: an evaluation of treatment with linezolid or daptomycin. | Q54500493 | ||
P433 | issue | 4 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | gram-positive bacteria | Q857288 |
organ transplantation | Q69253852 | ||
P304 | page(s) | 532-538 | |
P577 | publication date | 2014-05-19 | |
P1433 | published in | Transplant Infectious Disease | Q15749562 |
P1476 | title | Daptomycin is safe and effective for the treatment of gram-positive cocci infections in solid organ transplantation | |
P478 | volume | 16 |
Q57815117 | Management of bacterial and fungal infections in end stage liver disease and liver transplantation: Current options and future directions |
Q38845084 | Multidrug-resistant organisms in liver transplant: Mitigating risk and managing infections. |
Q41771325 | Role of daptomycin in the induction and persistence of the viable but non-culturable state of Staphylococcus aureus biofilms |
Q38757179 | Ultrasonography-driven combination antibiotic therapy with tigecycline significantly increases survival among patients with neutropenic enterocolitis following cytarabine-containing chemotherapy for the remission induction of acute myeloid leukemia. |
Search more.